1. Quantification of N-terminal amyloid-β isoforms reveals isomers are the most abundant form of the amyloid-β peptide in sporadic Alzheimer’s disease
- Author
-
Ian Birchall, Blaine R. Roberts, Larissa Lago, Kevin J. Barnham, Stephan Klatt, Soumya Mukherjee, Keyla Perez, Catriona McLean, and Colin L. Masters
- Subjects
Gene isoform ,Amyloid ,Peptide ,Disease ,amyloid-β ,Oligomer ,isomerization ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,chemistry.chemical_compound ,0302 clinical medicine ,long-lived peptide ,Biological Psychiatry ,mass spectrometry ,030304 developmental biology ,chemistry.chemical_classification ,Temporal cortex ,0303 health sciences ,biology ,AcademicSubjects/SCI01870 ,Chemistry ,peptide ,Psychiatry and Mental health ,Neurology ,Biochemistry ,biology.protein ,Original Article ,AcademicSubjects/MED00310 ,Antibody ,Alzheimer’s disease ,Isomerization ,030217 neurology & neurosurgery - Abstract
Plaques that characterize Alzheimer’s disease accumulate over 20 years as a result of decreased clearance of amyloid-β peptides. Such long-lived peptides are subjected to multiple post-translational modifications, in particular isomerization. Using liquid chromatography ion mobility separations mass spectrometry, we characterized the most common isomerized amyloid-β peptides present in the temporal cortex of sporadic Alzheimer’s disease brains. Quantitative assessment of amyloid-β N-terminus revealed that > 80% of aspartates (Asp-1 and Asp-7) in the N-terminus was isomerized, making isomerization the most dominant post-translational modification of amyloid-β in Alzheimer’s disease brain. Total amyloid-β1–15 was ∼85% isomerized at Asp-1 and/or Asp-7 residues, with only 15% unmodified amyloid-β1–15 left in Alzheimer’s disease. While amyloid-β4–15 the next most abundant N-terminus found in Alzheimer’s disease brain, was only ∼50% isomerized at Asp-7 in Alzheimer’s disease. Further investigations into different biochemically defined amyloid-β-pools indicated a distinct pattern of accumulation of extensively isomerized amyloid-β in the insoluble fibrillar plaque and membrane-associated pools, while the extent of isomerization was lower in peripheral membrane/vesicular and soluble pools. This pattern correlated with the accumulation of aggregation-prone amyloid-β42 in Alzheimer’s disease brains. Isomerization significantly alters the structure of the amyloid-β peptide, which not only has implications for its degradation, but also for oligomer assembly, and the binding of therapeutic antibodies that directly target the N-terminus, where these modifications are located., Mukherjee et al. report more than 80% of amyloid β N-terminus accumulating in sporadic Alzheimer’s disease is isomerized at Asp-1 and Asp-7 using ion mobility mass spectrometry. The discovery has implications for drug discovery, particularly immunotherapeutic strategies that often target the N-terminus of the peptide., Graphical Abstract Graphical Abstract
- Published
- 2021